They really to address the following:
- How is the roll out of PlusOne going? What has bee the feedback from customers? How will this drive increased profitability?
- What are the monetisation plans for tap-to-refill?
- What are the plans for monetisation of sales/dispensing data that will be available from pharmacies once PlusOne is in place? NostraData (A player in this field) is listed as a related party in the Prospectus. How are these companies working together.
Ann: MedAdvisor Quarterly Report & Appendix 4C, page-9
Add MDR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
30.0¢ |
Change
0.010(3.45%) |
Mkt cap ! $215.0M | |||
| Open | High | Low | Value | Volume |
| 29.0¢ | 30.0¢ | 27.5¢ | $254.8K | 889.6K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 39326 | 30.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 30.5¢ | 2917 | 1 |
View Market Depth
| Last trade - 16.10pm 15/11/2024 (20 minute delay) ? |
| MDR (ASX) Chart |
